CADL Stock Analysis: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$8.51
-0.76 (-8.20%)
▼
5d:
+2.53%
30d:
+11.53%
90d:
+72.27%
BUY
MODERATE Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called CADL this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 1.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CADL shows positive signals but monitor for confirmation. Market pricing in 1.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $8.51, which is considered slightly high relative to its 30-day fair value range of $7.04 to $8.79. The stock's valuation (Forward PE: 38.7) is in line with its historical norms (37.4). At these levels, the market is pricing in 1.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $7.90, while resistance sits at $9.57. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: CADL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.62 (+130.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CADL is in a strong uptrend. Immediate support is located at $7.90, while resistance sits at $9.57. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: CADL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.62 (+130.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.04 -
$8.79
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 130.6% below Wall St target ($19.62)
- NEUTRAL: Market pricing in 1.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$7.04 -
$8.79
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.90
Resistance Level
$9.57
Current Trend
Strong Uptrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
38.68
Wall Street Target
$19.63
(+130.6%)
Valuation Premium vs History
+1.1% premium
PE vs Historical
38.7 vs 37.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.1%
(market-implied from PE analysis)
1-Year Target
$8.60
(+1%)
2-Year Target
$8.70
(+2%)
3-Year Target
$8.79
(+3%)
3-Yr Target (if PE normalizes)
(PE: 39→37)
PE COMPRESSION
$8.50
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 06, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Paul B Manning
BUY
550458 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 63 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 67 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 56 HOLD |
